Magnus Persson, MD, PhD, Associate Professor
Chairman
Magnus is a Physician and Scientist, who early in his career successfully started a medical technology company (Aerocrine), led clinical trials at Sanofi and subsequently was a Partner in two life science Venture Capital firms, HealthCap in Stockholm and The Column Group in San Francisco. He has had a role in dozens of investments and exits. Lately he has been an independent Chairman/Board member in several private and public companies in the Nordics, as well as in the US, and worked on a weekly basis as a clinician. Magnus has been actively involved in a number of successful pharma spin-outs. He has experience from the academic incubator space as CEO at Karolinska Institutet Holding. Magnus is a Founder and Chairman of Eir Ventures Partners AB.
Gunilla Ekström, M.D., Ph.D.
Gunilla Ekström is a cofounder of Gesynta Pharma and serves as a member of several boards of private and public life science companies. Having worked some 30 years in the pharma industry, including companies such as Astra Zeneca, Orexo and Karolinska Development, she has extensive experience of managing advanced pre-clinical and clinical pharmaceutical development projects and organizations.
Patrik Strömberg, Ph.D., MBA
Currently CEO of AnaCardio AB, Patrik Strömberg has close to 20 years of experience from the pharmaceutical industry and has worked in leading roles in both R&D, innovation management and business development in companies such as AstraZeneca and, most recently, as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum (Sobi). He has a PhD in Biochemistry from Karolinska Institutet and earned an MBA from Stockholm University (Stockholm Business School).
Sara Mangsbo, Ph.D.
Sara Mangsbo, one of the founders of Strike Pharma, has over 15 years of experience in the field of immunotherapy both in the pre-clinical and clinical space. She is Associate Professor and senior lecturer in the Department of Pharmaceutical Biosciences at Uppsala University where she heads a team focused on immuno- oncology studies, specifically to improve immunotherapeutic treatments for solid tumors by developing novel immunotherapeutics and investigating their performance in new model systems.
Fredrik Lehmann, Ph.D., MBA
Fredrik Lehmann is a senior advisor at Flerie since 2026. Fredrik has held senior executive and operational roles at several biotech companies, including Oncopeptides (Head of Research and CMC), Recipharm (General Manager), and EpiEndo (CEO and CMC). He has also founded several life science companies, including OT Chemistry, which was acquired by Recipharm in 2015, Synartro and Renity Pharma. Fredrik is as a venture partner at Industrifonden and was an Entrepreneur in Residence at Sound Bioventures. Fredrik has a Ph.D. from the University of Gothenburg and an Executive MBA from the Stockholm School of Economics.